Not getting enough sleep
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Alcohol can increase the risk of hypoglycemia, particularly in patients with diabetes who are also taking insulin or sulfonylureas in combination with semaglutide
Referral to secondary care is indicated for severe or rapidly progressive neurological symptoms, diagnostic uncertainty, suspected bone marrow failure, or in pregnancy or paediatric cases
No peptide, including BPC-157, can reattach a torn labrum
Following the first treatment, approximately 3.6 pounds, or 24% of the total fat in this region, would be effectively reduced